Birchview Capital’s Voyager Therapeutics VYGR Stock Holding History

Birchview Capital’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263K	Buy	75,147 +229	+0.3%	+$868	0.12%	64
2026 Q1	$289K	Hold	74,918	–	–	0.16%	63
2025 Q4	$294K	Sell	74,918 -60,000	-44%	-$265K	0.17%	60
2025 Q3	$630K	Buy	+134,918	New	+$488K	0.48%	49
2020 Q4	–	Sell	-30,000	Closed	-$320K	–	49
2020 Q3	$320K	Hold	30,000	–	–	0.21%	42
2020 Q2	$379K	Hold	30,000	–	–	0.23%	41
2020 Q1	$274K	Hold	30,000	–	–	0.24%	38
2019 Q4	$419K	Hold	30,000	–	–	0.3%	38
2019 Q3	$516K	Hold	30,000	–	–	0.34%	28
2019 Q2	$817K	Hold	30,000	–	–	0.5%	21
2019 Q1	$574K	Sell	30,000 -3,000	-9%	-$39.1K	0.36%	28
2018 Q4	$310K	Hold	33,000	–	–	0.29%	36
2018 Q3	$624K	Hold	33,000	–	–	0.4%	28
2018 Q2	$645K	Hold	33,000	–	–	0.44%	24
2018 Q1	$620K	Sell	33,000 -10,000	-23%	-$216K	0.41%	21
2017 Q4	$714K	Buy	43,000 +19,000	+79%	+$326K	0.42%	19
2017 Q3	$494K	Buy	+24,000	New	+$271K	0.26%	23

Other funds holding VYGR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Birchview Capital's VYGR Position: Q2 2026 in Review

Birchview Capital increased its Voyager Therapeutics (VYGR) stake by 0.31% in Q2 2026, buying an estimated $868 and bringing the position to 75,147 shares worth $263K. The position accounts for 0.12% of the portfolio, ranked #64.

Birchview Capital first reported a position in VYGR in Q3 2017 and has held it in 17 quarters since. The position peaked at $817K in Q2 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

Birchview Capital held 75,147 shares of Voyager Therapeutics worth $263K as of Q2 2026.
Birchview Capital bought 229 Voyager Therapeutics shares in Q2 2026, an estimated $868.
Voyager Therapeutics made up 0.12% of Birchview Capital's portfolio in Q2 2026, its #64 holding.
Birchview Capital first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 17 quarters since.
Birchview Capital's Voyager Therapeutics position peaked at $817K in Q2 2019.
136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.